S&P 500   3,948.72
DOW   32,105.25
QQQ   309.75
Why Wall Street Loves These 3 Penny Stocks
Forbes mag says this strategy "like finding money in the street" (Ad)pixel
3 Leading Dividend Stocks Expected To Grow Earnings
Chewy Stock Is Setting Up For Long-Term Profitable Growth 
Forbes mag says this strategy "like finding money in the street" (Ad)pixel
Closing prices for crude oil, gold and other commodities
Low Volume Bunge Plunge Presents an Opportunity
Forbes mag says this strategy "like finding money in the street" (Ad)pixel
KB Home Strong Results Lift Prices
Carvana May Be Able To Reach Profitability This Year
S&P 500   3,948.72
DOW   32,105.25
QQQ   309.75
Why Wall Street Loves These 3 Penny Stocks
Forbes mag says this strategy "like finding money in the street" (Ad)pixel
3 Leading Dividend Stocks Expected To Grow Earnings
Chewy Stock Is Setting Up For Long-Term Profitable Growth 
Forbes mag says this strategy "like finding money in the street" (Ad)pixel
Closing prices for crude oil, gold and other commodities
Low Volume Bunge Plunge Presents an Opportunity
Forbes mag says this strategy "like finding money in the street" (Ad)pixel
KB Home Strong Results Lift Prices
Carvana May Be Able To Reach Profitability This Year
S&P 500   3,948.72
DOW   32,105.25
QQQ   309.75
Why Wall Street Loves These 3 Penny Stocks
Forbes mag says this strategy "like finding money in the street" (Ad)pixel
3 Leading Dividend Stocks Expected To Grow Earnings
Chewy Stock Is Setting Up For Long-Term Profitable Growth 
Forbes mag says this strategy "like finding money in the street" (Ad)pixel
Closing prices for crude oil, gold and other commodities
Low Volume Bunge Plunge Presents an Opportunity
Forbes mag says this strategy "like finding money in the street" (Ad)pixel
KB Home Strong Results Lift Prices
Carvana May Be Able To Reach Profitability This Year
S&P 500   3,948.72
DOW   32,105.25
QQQ   309.75
Why Wall Street Loves These 3 Penny Stocks
Forbes mag says this strategy "like finding money in the street" (Ad)pixel
3 Leading Dividend Stocks Expected To Grow Earnings
Chewy Stock Is Setting Up For Long-Term Profitable Growth 
Forbes mag says this strategy "like finding money in the street" (Ad)pixel
Closing prices for crude oil, gold and other commodities
Low Volume Bunge Plunge Presents an Opportunity
Forbes mag says this strategy "like finding money in the street" (Ad)pixel
KB Home Strong Results Lift Prices
Carvana May Be Able To Reach Profitability This Year
NASDAQ:HRTX

Heron Therapeutics - HRTX Price Target & Analyst Ratings

$2.06
+0.09 (+4.56%)
(As of 03/23/2023 12:00 AM ET)
Add
Compare
Today's Range
$1.96
▼
$2.10
50-Day Range
$1.97
▼
$3.25
52-Week Range
$1.96
▼
$6.38
Volume
2.61 million shs
Average Volume
1.69 million shs
Market Capitalization
$245.51 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.60

Heron Therapeutics Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Buy
Based on 1 Analyst Ratings

Consensus Analyst Price Target

$9.60
364.89% Upside
High Prediction$15.00
Average Prediction$9.60
Low Prediction$5.50
TypeCurrent
3/24/22 to 3/24/23		1 Month Ago
2/22/22 to 2/22/23		3 Months Ago
12/24/21 to 12/24/22		1 Year Ago
3/24/21 to 3/24/22
Consensus Rating
Buy
Buy
Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
1 Buy rating(s)
2 Buy rating(s)
2 Buy rating(s)
3 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$9.60$9.60$9.60$20.20
Predicted Upside364.89% Upside125.58% Upside125.58% Upside91.92% Upside
Get Heron Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for HRTX and its competitors with MarketBeat's FREE daily newsletter.

HRTX Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

HRTX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Heron Therapeutics Stock vs. The Competition

TypeHeron TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.64
2.47
Consensus RatingBuyBuyHold
Predicted Upside363.77% Upside1,922.77% Upside24.76% Upside
News Sentiment RatingNeutral News
Neutral News
Positive News

Historical Target Prices and Ratings

Export to Excel
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/15/2022Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower Target$15.00+368.75%
11/9/2022Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetBuy$10.00 ➝ $8.00+131.88%
8/15/2022Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower Target$5.50+2.42%
5/10/2022Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating		B. Folkes
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target$20.00 ➝ $12.00+232.41%
7/23/2021Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Biren Amin
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated RatingBuy$25.00+93.95%
5/13/2021Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Derek Archila
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated RatingBuy$27.00+64.43%
12/2/2020SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetOutperform$21.00 ➝ $24.00+37.14%
8/6/2020Northland Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Carl Byrnes
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated CoverageBuy$35.00+128.61%
5/26/2020Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoverageBuy$24.00+30.15%
5/18/2020FIX
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoverageAdd
(Data available from 3/24/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












HRTX Price Target - Frequently Asked Questions

What is Heron Therapeutics's consensus rating and price target?

According to the issued ratings of 1 analysts in the last year, the consensus rating for Heron Therapeutics stock is Buy based on the current 1 buy rating for HRTX. The average twelve-month price prediction for Heron Therapeutics is $9.60 with a high price target of $15.00 and a low price target of $5.50. Learn more on HRTX's analyst rating history.

Do Wall Street analysts like Heron Therapeutics more than its competitors?

Analysts like Heron Therapeutics more than other Medical companies. The consensus rating score for Heron Therapeutics is 3.00 while the average consensus rating score for medical companies is 2.64. Learn more on how HRTX compares to other companies.

Does Heron Therapeutics's stock price have much upside?

According to analysts, Heron Therapeutics's stock has a predicted upside of 153.86% based on their 12-month price targets.


Stock Ratings Reports and Tools

Today's Ratings:
Top Rated Stocks:
More Ratings Tools:
Ratings for Popular Stocks:
This page (NASDAQ:HRTX) was last updated on 3/24/2023 by MarketBeat.com Staff